Cardiometabolic disease is the number one cause of mortality, accounting for 31% of all global deaths—75% of which occur in low- and middle-income countries.
Cardiometabolic disease is not a single ailment, but rather a spectrum of conditions.1 Early intervention is crucial to prevent complications. Most cardiovascular diseases can be prevented by addressing certain risk factors, such as tobacco use, unhealthy diet and obesity, physical inactivity, and harmful use of alcohol. However, the reality of many situations is that early warning signs are ignored and diagnostic solutions are required to inform appropriate intervention.
American College for Cardiology. Cardiometabolic Initiatives. https://www.acc.org/tools-and-practice-support/quality-programs/cardiometabolic-health-alliance. Accessed March 9, 2021.
We are focused on bringing better diagnostics solutions to support early intervention and improve outcomes.
Today, advanced technologies and our evolved understanding of disease present new opportunities to personalise treatment, reduce unnecessary costs, and protect people in their time of need. The use of tests to assess risk, screen, diagnose, predict, and monitor cardiac disease have been essential tools in protecting patients, helping to reduce anxiety, avoid overcrowding of the emergency department, and help save lives.
The Head of the Heart Institute at Hospital Universitari Germans Trias i Pujol in Barcelona, Spain, talks about heart failure and how biomarkers play a role in patients’ management.
Paul has been diagnosed with heart failure and now he has many questions that he can't answer. Learn how biomarkers allow physicians to make the right decisions in heart failure management along the patients' journey.